We aim to identify genetic alterations that influence cancer development, progression and therapeutic responses, in particular for prostate cancer, and further develop them into biomarkers for cancer diagnosis and therapeutic stratification, with a current focus on circulating biomarkers.
Non-invasive Detection of Clinically Significant Prostate Cancer Using Circulating Tumor Cells. J Urol (2019) [Epub ahead of print]. PMID: 31389764
The novel association of circulating tumor cells and circulating megakaryocytes with prostate cancer prognosis. Clin Cancer Res (2017) 23(17):5112-5122. PMID: 28615267
DNA replication-dependent induction of gene proximity by androgen. Hum Mol Genet (2015) 15;24(4):963-71. PMID: 25281662
Identification of ZDHHC14 as a novel human tumour suppressor gene. J Pathol (2014) 232(5):566-77. PMID: 24407904
I have set up a research team devoted to cancer genetic studies and biomarker development, in particular in male urological cancers. The mission of the research team is to reduce motility and morbidity of cancer patients by understanding cancer development and progression mechanisms and facilitating precision medicine through the development of efficient cancer detection, prognostic and treatment response prediction/monitoring biomarkers.
Our past work have been mainly focused on identification of genetic alterations and genetic mechanisms in cancer development, progression and therapeutic response. Recently, our research work moved into circulation biomarker development, including CTCs, exosome and other cells, for cancer diagnosis, prognosis and prediction/monitoring of cancer progression and therapeutic response.
There are currently two main research areas of interest:
Erratum to: Genome-wide association study identifies susceptibility loci for B-cell childhood acute lymphoblastic leukemia (Nature Communications, (2018), 9, 1, (1340), 10.1038/s41467-018-03178-z) Vijayakrishnan J, Studd J, Broderick P et al. Nature Communications (2019) 10(7)
Erratum to: Genome-wide association study of classical Hodgkin lymphoma identifies key regulators of disease susceptibility (Nature Communications, (2017), 8, 1, (1892), 10.1038/s41467-017-00320-1) Sud A, Thomsen H, Law PJ et al. Nature Communications (2019) 10(7)
Erratum to: Germline variation at 8q24 and prostate cancer risk in men of European ancestry (Nature Communications, (2018), 9, 1, (4616), 10.1038/s41467-018-06863-1) Matejcic M, Saunders EJ, Dadaev T et al. Nature Communications (2019) 10(7)
Erratum to: Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma (Nature Communications, (2018), 9, 1, (3707), 10.1038/s41467-018-04989-w) Went M, Sud A, Försti A et al. Nature Communications (2019) 10(7)
Erratum to: Large-scale transcriptome-wide association study identifies new prostate cancer risk regions (Nature Communications, (2018), 9, 1, (4079), 10.1038/s41467-018-06302-1) Mancuso N, Gayther S, Gusev A et al. Nature Communications (2019) 10(7)
Reply by Authors. Xu L, Mao X, Grey A et al. J Urol (2019) (2) 10109701JU0000602796
Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches Song D, Powles T, Shi L et al. Journal of Pathology (2019) 249(7) 151-165
Noninvasive Detection of Clinically Significant Prostate Cancer Using Circulating Tumor Cells. Xu L, Mao X, Grey A et al. The Journal of Urology 203(1) 101097JU000000000000-101097JU000000000000
Observation of Light-by-Light Scattering in Ultraperipheral Pb+Pb Collisions with the ATLAS Detector Aad G, Abbott B, Abbott DC et al. Physical Review Letters (2019) 123(7)
Comparison of Fragmentation Functions for Jets Dominated by Light Quarks and Gluons from pp and Pb+Pb Collisions in ATLAS. Aaboud M, Aad G, Abbott B et al. Physical Review Letters (2019) 123(1) 042001-042001
Xueying Mao, Elzbieta Stankiewicz
Tanyu Guo, Caitlin Davis, Yeuzhou Zhang